The Immunology of Dengue, Chikungunya and Zika Virus: Implications for Vaccines and Vaccine Development
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 1789
Special Issue Editor
Special Issue Information
Dear Colleagues,
Dengue viruses (DENVs) are a leading cause of viral infections and disease in tropical and subtropical regions worldwide. Chikungunya virus (CHIKV) and Zika virus (ZIKV) have also spread globally in more recent years, causing significant outbreaks. Each of these viruses is transmitted between individuals by Aedes species mosquitoes (notably Ae. aegypti and Ae. albopictus); thus, as the vectors expand into previously more temperate regions, so too does the risk of infection. Despite these risks, the availability of vaccines against DENV, CHIKV, and ZIKV, which are both safe and efficacious, is either limited or unavailable. Confounding the development and safety of vaccines is a detailed understanding of the immunological response to infection with these viruses following natural transmission via the mosquito. Traditionally, immunological studies with DENV, CHIKV, and ZIKV have relied on needle inoculation of animal models; however, more recent studies suggest that mosquito saliva contains excipients that can perpetuate infection. Thus, a detailed understanding of the role of mosquito saliva as well as specific excipients found in mosquito saliva on the immunological response to viral infection is needed in order to fully appreciate the protective efficacy and risks of vaccination against DENV, CHIKV, and ZIKV.
Dr. Jonathan O. Rayner
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dengue
- chikungunya
- Zika
- mosquito
- saliva
- immunity
- innate
- adaptive
- immunomodulation
- vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
